Patent · US Active

Soluble guanylate cyclase activators for treating portal hypertension

US12226411B2 · kind B2 · utility

0Cited by

2References

13Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Judith Maria Ertle · Ingelheim am Rhein, DE
Jochen Huber · Mittelbiberach, DE
Leo John SEMAN · Salem, US

Key dates

Filing date	Mar 20, 2023
Grant date	Feb 18, 2025
Priority date	—
Expiry date	Jun 5, 2043

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P1/16
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to methods for treating patients with compensated cirrhosis, comprising administering to a patient in need thereof a therapeutically effective amount of a soluble guanylate cyclase (sGC) activator, or a pharmaceutically acceptable salt thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.